Highlights Applied Therapeutics, Inc.

Equities

APLT

US03828A1016

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
4.44 ^USD	+0.45%		+3.02%	+32.54%

Apr. 15	Applied Therapeutics, Inc. Announces Management Changes	CI
Mar. 28	Applied Therapeutics Shares Slip 13% After FDA Extends Drug Review	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Applied Therapeutics Shares Slip 13% After FDA Extends Drug Review	Mar. 28	DJ
Applied Therapeutics Gets NDA Review Period Extension for Galactosemia Treatment -- Shares Fall After Hours	Mar. 28	MT
US FDA extends review of Applied Therapeutics' genetic disease drug	Mar. 28	RE
Applied Therapeutics, Inc. Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia	Mar. 28	CI
Applied Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Earnings Flash (APLT) APPLIED THERAPEUTICS Reports Q4 Revenue $10M	Mar. 06	MT
Applied Therapeutics Shares Surge on FDA Review, $100 Million Funding Round	Feb. 28	DJ
Applied Therapeutics Says Phase 3 Trial of Govorestat Meets Interim Primary Goal; Shares Rise	Feb. 16	MT
Applied Therapeutics, Inc. Announces Positive Interim 12-Month Results from the Ongoing Phase 3 Inspire Trial	Feb. 15	CI
Applied Therapeutics, Inc. Announces Positive Results from 12-Month Interim Analysis of Govorestat (At-007) in the Ongoing Inspire Phase 3 Trial in Sorbitol Dehydrogenase Deficiency	Feb. 15	CI
Waning Rate Cut Hopes, Employment Situation Report Push Down Exchange-Traded Funds, Equity Futures Pre-Bell Friday	Jan. 05	MT
Applied Therapeutics, Inc. Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy	Jan. 04	CI
Applied Therapeutics Shares Hit 52-Week High on Govorestat Filings	Jan. 03	DJ
Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia	Jan. 03	CI
Applied Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Applied Therapeutics, Inc. Announces Successful Pre-Nda Meeting with the Fda and Confirms Plans to Submit Nda for Govorestat (At-007) for Treatment of Classic Galactosemia to Fda in Fourth Quarter 2023	23-09-06	CI
Applied Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Applied Therapeutics' AT-007 Receives Orphan Drug Designation in Europe	23-05-25	MT
Applied Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Earnings Flash (APLT) APPLIED THERAPEUTICS Reports Q1 Revenue $10.7M	23-05-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Applied Therapeutics, Inc.

Equities

APLT

US03828A1016

Highlights

Filters